Frank Guarnieri's Contact Details

Frank Guarnieri's Company Details

PAKA Pulmonary Pharmaceuticals; Inc.

Acton, Massachusetts, United States • 1 - 10 Employees
Pharmaceuticals

PAKA Pulmonary Pharmaceuticals is an early-stage biopharmaceutical company developing new drugs for acute and chronic lung diseases, a potential US market of over $30B. Our proprietary technology overcomes the two key obstacles to the successful treatment of lung diseases: delivering an active agent to the vast lung surface area and keeping it there at an effective concentration without systemic side effects. We accomplish this by attaching an active small molecule drug to a peptide from human Lung Surfactant Protein B and delivering the conjugate by inhalation. We intend to use this approach to create patentable new drugs for a range of lung diseases and to develop these products through collaboration and licensing arrangements. Because we can work with active molecules for which the mechanism of action and pharmacology are known, while achieving dramatic improvements in efficacy and safety and obtaining new composition of matter patent coverage, we expect to create substantial value for our investors using a capital efficient semi-virtual business model.